Article · DOAJ · January 1, 2017

ESTIMATION OF SAMARIUM-153 OXABIFORE THERAPY RESULTS OF METASTATIC BONE DISEASE IN COMBINED TREATMENT WITH BISPHOSPHONATES AND IN MONO REGIME BY SEMI-QUANTITATIVE ANALYZE OF WB BONE SCANS

N. V. Rasulova, Д. Т. Арыбжанов, Vladimir Lyubshin, R. Karrer, A. Bartl, Sz. Wlodarczyk

Read on doaj.orgDOI 10.24060/2076-3093-2014-0-1-2-32-38

Abstract

Results of treatment of 54 patients: 43 female with breast cancer and 11 males with prostatic cancer with metastatic bone disease treated with using Sm-153 are assessed. According to semi-quantitative analyze of WB bone scans the most effects results were found in a group of patients who received combined therapy and there where regression of osteoblastic bone metastases in 84,2% of cases, progression is in 7,8%, the same number of patients had simultaneous process: progression and regression. However in patients who were treated with using Sm-153 oxabifore as mono therapy regression of bone metastases was found in 68% of cases, progression is in 25% of the patients and stabilization of metastatic bone disease is in 6,25% of cases.

Bone health and treatmentsManagement of metastatic bone diseaseRadiopharmaceutical Chemistry and Applicationsradionuclide therapybone metastasisbreast cancer

ESTIMATION OF SAMARIUM-153 OXABIFORE THERAPY RESULTS OF METASTATIC BONE DISEASE IN COMBINED TREATMENT WITH BISPHOSPHONATES AND IN MONO REGIME BY SEMI-QUANTITATIVE ANALYZE OF WB BONE SCANS

Abstract

More by Marat Khodjibekov